DK2925338T3 - Frysetørret formulering af tat-nr2b9c - Google Patents
Frysetørret formulering af tat-nr2b9c Download PDFInfo
- Publication number
- DK2925338T3 DK2925338T3 DK13859059.1T DK13859059T DK2925338T3 DK 2925338 T3 DK2925338 T3 DK 2925338T3 DK 13859059 T DK13859059 T DK 13859059T DK 2925338 T3 DK2925338 T3 DK 2925338T3
- Authority
- DK
- Denmark
- Prior art keywords
- nr2b9c
- tat
- freeze
- dried formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261730952P | 2012-11-28 | 2012-11-28 | |
| PCT/US2013/071755 WO2014085349A1 (en) | 2012-11-28 | 2013-11-25 | Lyophilized formulation of tat-nr2b9c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2925338T3 true DK2925338T3 (da) | 2019-05-06 |
Family
ID=50828392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13859059.1T DK2925338T3 (da) | 2012-11-28 | 2013-11-25 | Frysetørret formulering af tat-nr2b9c |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140162957A1 (da) |
| EP (1) | EP2925338B8 (da) |
| JP (1) | JP6427104B2 (da) |
| KR (1) | KR102166374B1 (da) |
| CN (2) | CN105101986B (da) |
| AU (1) | AU2013352437B2 (da) |
| CA (1) | CA2892965C (da) |
| DK (1) | DK2925338T3 (da) |
| ES (1) | ES2725598T3 (da) |
| HK (1) | HK1215793A1 (da) |
| HR (1) | HRP20190707T1 (da) |
| HU (1) | HUE043820T2 (da) |
| LT (1) | LT2925338T (da) |
| MX (1) | MX365325B (da) |
| PL (1) | PL2925338T3 (da) |
| PT (1) | PT2925338T (da) |
| SI (1) | SI2925338T1 (da) |
| TR (1) | TR201905787T4 (da) |
| WO (1) | WO2014085349A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| EP3148568A4 (en) * | 2014-05-28 | 2018-01-17 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
| LT3149048T (lt) | 2014-05-28 | 2020-05-11 | Nono Inc. | Tat-nr2b9c chlorido druska |
| EP3247400A1 (en) * | 2015-01-18 | 2017-11-29 | Biogen MA Inc. | Formulations and screening of biological therapeutic agents |
| EP3450446A4 (en) * | 2016-04-27 | 2019-03-06 | Biocells (Beijing) Biotech Co., Ltd. | METHOD OF TREATING ADVERSE NEUROTOXICITY-RELATED INJURIES |
| CN106619170A (zh) * | 2016-10-26 | 2017-05-10 | 暨南大学 | 包含stp和生长因子的活性组合物及其化妆品或护肤品 |
| CN110627877A (zh) * | 2019-09-25 | 2019-12-31 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7510824B2 (en) * | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| CA2551190A1 (en) * | 2003-12-23 | 2005-07-07 | Nono Inc. | Polypeptides for modulating binding of trp channel proteins and trp-associated proteins. |
| GB0329918D0 (en) * | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| EP1910552A4 (en) * | 2005-06-23 | 2009-01-07 | Arbor Vita Corp | METHOD AND COMPOSITIONS FOR MODULATING COX |
| US8633160B2 (en) * | 2005-12-30 | 2014-01-21 | Nono Inc. | Small molecule inhibitors of PDZ interactions |
| EP2021474A2 (en) * | 2006-05-05 | 2009-02-11 | Transtech Pharma, Inc. | Rage fusion proteins, formulations, and methods of use thereof |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| AU2009288088B2 (en) * | 2008-09-03 | 2014-12-04 | Nono Inc. | Agents and methods for treatment of pain |
| US8099602B2 (en) * | 2008-09-26 | 2012-01-17 | Mykonos Software, Inc. | Methods for integrating security in network communications and systems thereof |
| PL2440231T3 (pl) * | 2009-06-10 | 2020-05-18 | Nono Inc. | Jednoczesne podawanie połączonego z peptydem internalizacyjnym tat środka oraz inhibitora degranulacji komórek tucznych |
| WO2010144721A2 (en) * | 2009-06-10 | 2010-12-16 | Arbor Vita Corporation | Model systems and treatment regimes for treatment of neurological disease |
| ES2655112T3 (es) * | 2010-08-12 | 2018-02-16 | Nono Inc. | Tratamiento de una lesión penetrante en el cerebro |
-
2013
- 2013-11-25 AU AU2013352437A patent/AU2013352437B2/en active Active
- 2013-11-25 ES ES13859059T patent/ES2725598T3/es active Active
- 2013-11-25 TR TR2019/05787T patent/TR201905787T4/tr unknown
- 2013-11-25 JP JP2015545156A patent/JP6427104B2/ja active Active
- 2013-11-25 PL PL13859059T patent/PL2925338T3/pl unknown
- 2013-11-25 MX MX2015006784A patent/MX365325B/es active IP Right Grant
- 2013-11-25 CA CA2892965A patent/CA2892965C/en active Active
- 2013-11-25 WO PCT/US2013/071755 patent/WO2014085349A1/en active Application Filing
- 2013-11-25 SI SI201331425T patent/SI2925338T1/sl unknown
- 2013-11-25 KR KR1020157017140A patent/KR102166374B1/ko active IP Right Grant
- 2013-11-25 DK DK13859059.1T patent/DK2925338T3/da active
- 2013-11-25 LT LTEP13859059.1T patent/LT2925338T/lt unknown
- 2013-11-25 PT PT13859059T patent/PT2925338T/pt unknown
- 2013-11-25 HU HUE13859059A patent/HUE043820T2/hu unknown
- 2013-11-25 CN CN201380071653.2A patent/CN105101986B/zh active Active
- 2013-11-25 EP EP13859059.1A patent/EP2925338B8/en active Active
- 2013-11-25 CN CN201810971184.4A patent/CN109106941A/zh active Pending
- 2013-11-26 US US14/089,752 patent/US20140162957A1/en not_active Abandoned
-
2016
- 2016-04-01 HK HK16103755.1A patent/HK1215793A1/zh unknown
-
2019
- 2019-04-16 HR HRP20190707TT patent/HRP20190707T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2725598T3 (es) | 2019-09-25 |
| KR102166374B1 (ko) | 2020-10-15 |
| HK1215793A1 (zh) | 2016-09-15 |
| SI2925338T1 (sl) | 2019-09-30 |
| BR112015012422A2 (pt) | 2017-09-12 |
| KR20150094656A (ko) | 2015-08-19 |
| CA2892965A1 (en) | 2014-06-05 |
| AU2013352437B2 (en) | 2018-04-12 |
| HUE043820T2 (hu) | 2019-09-30 |
| EP2925338A4 (en) | 2016-05-25 |
| JP6427104B2 (ja) | 2018-11-21 |
| PL2925338T3 (pl) | 2019-11-29 |
| CN105101986B (zh) | 2018-09-25 |
| CA2892965C (en) | 2021-06-01 |
| PT2925338T (pt) | 2019-05-31 |
| MX365325B (es) | 2019-05-29 |
| EP2925338B1 (en) | 2019-03-27 |
| WO2014085349A1 (en) | 2014-06-05 |
| CN109106941A (zh) | 2019-01-01 |
| JP2016502537A (ja) | 2016-01-28 |
| EP2925338A1 (en) | 2015-10-07 |
| MX2015006784A (es) | 2015-10-29 |
| CN105101986A (zh) | 2015-11-25 |
| LT2925338T (lt) | 2019-05-10 |
| TR201905787T4 (tr) | 2019-05-21 |
| AU2013352437A1 (en) | 2015-07-09 |
| US20140162957A1 (en) | 2014-06-12 |
| HRP20190707T1 (hr) | 2019-10-04 |
| EP2925338B8 (en) | 2019-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3725778T3 (da) | Formuleringer af enzalutamid | |
| CO7061086A2 (es) | Combinaciones de compuestos activos | |
| DK3336097T3 (da) | Fremstilling af ikke-krystallinsk obeticholsyre | |
| DK2845905T3 (da) | Fremstilling af oligosaccharider | |
| DK2858671T3 (da) | Antistofformulering | |
| CO6801776A2 (es) | Cosmético | |
| BR112015002651A2 (pt) | composições cosméticas | |
| DK2890397T3 (da) | Antiprolactinreceptor-antistofformulering | |
| DK2846809T3 (da) | Behandling af myelosuppression | |
| BR112014032798A2 (pt) | composição | |
| AR092198A1 (es) | Derivados de pirazolopirimidinas | |
| DK2925338T3 (da) | Frysetørret formulering af tat-nr2b9c | |
| DK3461895T3 (da) | Modulation af ube3a-ats-ekspression | |
| DK2841054T3 (da) | Injicerbart præparat | |
| BR112014029176A2 (pt) | formulações injetáveis de aprepitante | |
| DK2822568T3 (da) | Anvendelser af caseinsammensætninger | |
| DK2827862T3 (da) | Formuleringer af bendamustin | |
| BR112014000015A2 (pt) | formulação | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| DK2868318T3 (da) | Injicerbar formulering | |
| DK2894998T3 (da) | Rotation af kegle | |
| DK2812013T3 (da) | Formulering til behandling af IBS | |
| BR112014032712A2 (pt) | composição | |
| DK2828396T3 (da) | Fremgangsmåde til fremstillingen af g-csf | |
| FR2995524B1 (fr) | Prothese endo-urinaire |